Drug/Software Combo Pathway Coming Soon To US FDA, Gottlieb Says
Executive Summary
Under a new regulatory platform, drugs could soon be approved with accompanying software applications that could monitor adverse events or patient compliance without a separate pre-market device review.
You may also be interested in...
US FDA Preparing For New 'Combination Product Agreement Meetings'
Cures legislation offers more development certainty for sponsors by allowing informal agreements with the agency on pre- and postmarket issues.
US FDA Commish Defends Approach To Apple Approvals
After industry stakeholders raised concerns that Apple may have received preferential treatment when US FDA approved heart-rhythm apps on the Apple Watch Series 4, Commissioner Scott Gottlieb states in a blog post that the agency's approach was in accordance with its standard procedures and reflect the benefit of early interaction with FDA.
US FDA's Digital Health Plan Could Brighten OTC Device Outlook
FDA says its "traditional approach" for hardware-based medical devices of moderate and higher risks "is not well suited for the faster iterative design, development and type of validation used for software-based medical technologies. Digital technologies such as mobile apps likely will have a role in facilitating additional Rx-to-OTC drug switches.